HomeAbout UsNewsContact Us
Jan 21, 2012
CUBRC Awarded BARDA Contract Worth up to $67M
Oct 11, 2011
CUBRC Awarded $36 Million NIAID Contract
Jul 13, 2011
Michael Holden to Receive AIAA Honor
May 25, 2011
MILITARY $725,000 Federal Contract Awarded CUBRC
May 17, 2011
CUBRC Inc. awarded $562,245 Federal contract
News & Events
October 11, 2011 « Back To News
CUBRC Awarded $36 Million NIAID Contract

CUBRC Awarded NIAID Contract Worth up to $36 Million for the Development of a Novel Tetracycline-Based Antibiotic


Buffalo, NY – October 11, 2011 – CUBRC, Inc.’s President and CEO, Tom McMahon announced today that CUBRC’s Biological and Medical Sciences team has received a five-year contract worth up to $36 million from the National Institute of Allergy and Infectious Disease (NIAID), a part of the National Institutes of Health (NIH). CUBRC and its team member, Tetraphase Pharmaceuticals, Inc., will be developing, manufacturing and clinically evaluating a novel tetracycline antibiotic for respiratory diseases caused by biodefense and antibiotic-resistant public health pathogens.

Today’s research and development programs for the treatment of diseases from biological threats emphasize broad-spectrum therapeutics effective against multiple types of infections instead of a single disease. CUBRC will be leveraging its technical expertise in Biological Defense-related R&D and its experience leading large federal government contracts to collaborate with Tetraphase and jointly execute key development, manufacturing, and clinical activities to position the drug candidate known as TP-271, which was discovered and patented by Tetraphase, for further development against important biothreat agents including Francisella tularnesis, which causes tularemia, Yersinia pestis, which causes bubonic plague, and Bacillus anthracis, which causes anthrax disease, as well as bacterial pathogens associated with community-acquired bacterial pneumonia. The contract has been awarded with a 25-month base period with committed funding of $5.8 million and subsequent options that, when exercised, could bring the total value of the contract award to almost $36 million.

Mr. McMahon stated that CUBRC owes a debt of gratitude to U.S. Congresswoman Louise Slaughter, who by securing federal funding over several years, assisted CUBRC in developing capabilities necessary to compete successfully for this type of program.

David Mangino, Vice President of CUBRC’s Chemical and Biological Defense Sector explained that “CUBRC has been able to leverage funding secured by Congresswoman Louise Slaughter to build our in-house biomedical capabilities, which in turn we used to position CUBRC to bid and win this full and open competitive NIAID procurement against elite level drug development competitors. We are truly thankful for her efforts and for NIAID’s confidence in our proposal to develop the next generation of treatments for biodefense and public health indications.” When informed of the award, Slaughter stated that CUBRC’s work in this area over the past 10 years is critical and that “antibiotic-resistance is becoming a serious threat to the health of our population and if not addressed in a timely and effective manner, it has the potential to negatively impact our national security.” She added, “I want to congratulate my friends at CUBRC. The research and advanced development that will result from this program will allow them to continue to build capability in this area, which it will use to secure new programs in the future, all while protecting the health of our Nation’s warfighters and civilians.”

About CUBRC, Inc.
 
CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Public Safety and Infrastructure, Information Fusion, Command and Control, and Hypersonics. To learn more about CUBRC, please visit www.cubrc.org.

About Tetraphase Pharmaceuticals, Inc.
 
Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistant and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com.

About NIAID
 
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research - at the National Institutes of Health (NIH), throughout the United States, and worldwide - to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov. The NIH - The U.S. Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Professional Services | Public Health & Safety | Medical Biotechnology | Chemical & Biological Defense | Information Exploitation | Hypersonics
Home | About Us | News | Contact Us ©2014CUBRC. All Rights Reserved Produced By VertaSource